Cargando…
Sirtinol promotes PEPCK1 degradation and inhibits gluconeogenesis by inhibiting deacetylase SIRT2
Phosphoenolpyruvate carboxykinase 1 (PEPCK1) is the critical enzyme for gluconeogenesis and is linked with type II diabetes. Previous studies have found that SIRT2, a deacetylase, plays an important role in deacetylating PEPCK1 and little is known about the anti-diabetic activity of SIRT2 inhibitors...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428341/ https://www.ncbi.nlm.nih.gov/pubmed/28127057 http://dx.doi.org/10.1038/s41598-017-00035-9 |
_version_ | 1783235797981331456 |
---|---|
author | Zhang, Mingming Pan, Yida Dorfman, Robert G. Yin, Yuyao Zhou, Qian Huang, Shan Liu, Jie Zhao, Shimin |
author_facet | Zhang, Mingming Pan, Yida Dorfman, Robert G. Yin, Yuyao Zhou, Qian Huang, Shan Liu, Jie Zhao, Shimin |
author_sort | Zhang, Mingming |
collection | PubMed |
description | Phosphoenolpyruvate carboxykinase 1 (PEPCK1) is the critical enzyme for gluconeogenesis and is linked with type II diabetes. Previous studies have found that SIRT2, a deacetylase, plays an important role in deacetylating PEPCK1 and little is known about the anti-diabetic activity of SIRT2 inhibitors. In this study, we investigated the anti-diabetic effects of sirtinol, a SIRT2 inhibitor, on cell gluconeogenesis in vivo and in vitro. Immunoblotting analysis revealed that sirtinol significantly decreased the protein level of PEPCK1, and was accompanied by the hyperacetylation of PEPCK1 as well as decreased glucose output in a dose-dependent manner. Furthermore, sirtinol exerted little impact on endogenous PEPCK1 levels in SIRT2-knockdown cells. The in vitro experiments further confirmed the in vivo data; sirtinol decreased liver PEPCK1 protein level and prevented pyruvate-induced blood glucose from increasing. Based on our results, the rate-limiting enzyme PEPCK1 is the primary target of sirtinol, and the inhibition of SIRT2 activity may play an important role in cell gluconeogenesis. Thus, SIRT2 may be a novel molecular target for diabetes therapy and may thus shed light on the underlying diabetes treatment mechanisms of sirtinol. |
format | Online Article Text |
id | pubmed-5428341 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-54283412017-05-15 Sirtinol promotes PEPCK1 degradation and inhibits gluconeogenesis by inhibiting deacetylase SIRT2 Zhang, Mingming Pan, Yida Dorfman, Robert G. Yin, Yuyao Zhou, Qian Huang, Shan Liu, Jie Zhao, Shimin Sci Rep Article Phosphoenolpyruvate carboxykinase 1 (PEPCK1) is the critical enzyme for gluconeogenesis and is linked with type II diabetes. Previous studies have found that SIRT2, a deacetylase, plays an important role in deacetylating PEPCK1 and little is known about the anti-diabetic activity of SIRT2 inhibitors. In this study, we investigated the anti-diabetic effects of sirtinol, a SIRT2 inhibitor, on cell gluconeogenesis in vivo and in vitro. Immunoblotting analysis revealed that sirtinol significantly decreased the protein level of PEPCK1, and was accompanied by the hyperacetylation of PEPCK1 as well as decreased glucose output in a dose-dependent manner. Furthermore, sirtinol exerted little impact on endogenous PEPCK1 levels in SIRT2-knockdown cells. The in vitro experiments further confirmed the in vivo data; sirtinol decreased liver PEPCK1 protein level and prevented pyruvate-induced blood glucose from increasing. Based on our results, the rate-limiting enzyme PEPCK1 is the primary target of sirtinol, and the inhibition of SIRT2 activity may play an important role in cell gluconeogenesis. Thus, SIRT2 may be a novel molecular target for diabetes therapy and may thus shed light on the underlying diabetes treatment mechanisms of sirtinol. Nature Publishing Group UK 2017-02-28 /pmc/articles/PMC5428341/ /pubmed/28127057 http://dx.doi.org/10.1038/s41598-017-00035-9 Text en © The Author(s) 2017 This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Zhang, Mingming Pan, Yida Dorfman, Robert G. Yin, Yuyao Zhou, Qian Huang, Shan Liu, Jie Zhao, Shimin Sirtinol promotes PEPCK1 degradation and inhibits gluconeogenesis by inhibiting deacetylase SIRT2 |
title | Sirtinol promotes PEPCK1 degradation and inhibits gluconeogenesis by inhibiting deacetylase SIRT2 |
title_full | Sirtinol promotes PEPCK1 degradation and inhibits gluconeogenesis by inhibiting deacetylase SIRT2 |
title_fullStr | Sirtinol promotes PEPCK1 degradation and inhibits gluconeogenesis by inhibiting deacetylase SIRT2 |
title_full_unstemmed | Sirtinol promotes PEPCK1 degradation and inhibits gluconeogenesis by inhibiting deacetylase SIRT2 |
title_short | Sirtinol promotes PEPCK1 degradation and inhibits gluconeogenesis by inhibiting deacetylase SIRT2 |
title_sort | sirtinol promotes pepck1 degradation and inhibits gluconeogenesis by inhibiting deacetylase sirt2 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428341/ https://www.ncbi.nlm.nih.gov/pubmed/28127057 http://dx.doi.org/10.1038/s41598-017-00035-9 |
work_keys_str_mv | AT zhangmingming sirtinolpromotespepck1degradationandinhibitsgluconeogenesisbyinhibitingdeacetylasesirt2 AT panyida sirtinolpromotespepck1degradationandinhibitsgluconeogenesisbyinhibitingdeacetylasesirt2 AT dorfmanrobertg sirtinolpromotespepck1degradationandinhibitsgluconeogenesisbyinhibitingdeacetylasesirt2 AT yinyuyao sirtinolpromotespepck1degradationandinhibitsgluconeogenesisbyinhibitingdeacetylasesirt2 AT zhouqian sirtinolpromotespepck1degradationandinhibitsgluconeogenesisbyinhibitingdeacetylasesirt2 AT huangshan sirtinolpromotespepck1degradationandinhibitsgluconeogenesisbyinhibitingdeacetylasesirt2 AT liujie sirtinolpromotespepck1degradationandinhibitsgluconeogenesisbyinhibitingdeacetylasesirt2 AT zhaoshimin sirtinolpromotespepck1degradationandinhibitsgluconeogenesisbyinhibitingdeacetylasesirt2 |